HB168

HB168 is a long-acting triple receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Developed by Huabao Pharmaceutical, this peptide-based therapeutic is intended for the treatment of metabolic conditions such as type 2 diabetes mellitus and obesity. By integrating the pharmacological actions of three distinct incretin and metabolic hormones, HB168 aims to achieve synergistic effects on glucose homeostasis, appetite suppression, and energy expenditure. The activation of GLP-1R and GIPR enhances insulin secretion and improves insulin sensitivity, while GCGR activation promotes thermogenesis and lipid metabolism, potentially leading to more significant weight loss and glycemic control than existing mono- or dual-agonist therapies.